Literature DB >> 2252446

Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results.

C W Olanow1, W Koller, C G Goetz, G T Stebbins, D W Cahill, L L Gauger, R Morantz, R D Penn, C M Tanner, H L Klawans.   

Abstract

Eighteen of 19 patients who underwent autologous adrenal medullary transplantation to the right caudate nucleus have been followed up for 18 months. During the course of this study, a statistically significant improvement was noted in percent "on" time, percent "on" time without dyskinesia, activity of daily living (ADL) scores during the "on" stages, and ADL, motor, and Schwab-England scores during the "off" stages. Benefits tended to be maximal at 6 months and to gradually lessen thereafter, although statistically significant improvement in comparison with baseline was still present at 18 months for ADL, motor, and Hoehn-Yahr scores during the "off" stages. Almost all parameters had deteriorated by 18 months compared with 12 months, including those remaining significantly improved in comparison with baseline. These patterns were similar for each of the three participating centers. Complications were largely restricted to the perioperative period.

Entities:  

Mesh:

Year:  1990        PMID: 2252446     DOI: 10.1001/archneur.1990.00530120030006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.

Authors:  Timothy J Collier; Jennifer O'Malley; David J Rademacher; Jennifer A Stancati; Kellie A Sisson; Caryl E Sortwell; Katrina L Paumier; Kibrom G Gebremedhin; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2015-03-11       Impact factor: 5.996

2.  Unfavorable outcome of adrenal medullary transplant for Parkinson's disease.

Authors:  L S Forno; J W Langston
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

3.  Re-initiated growth from mature ventral mesencephalon: an in oculo transplant study of nigrostriatal co-grafts.

Authors:  I Strömberg; M Johansson
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 4.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

5.  Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease.

Authors:  Emad S Farag; Harry V Vinters; Jeff Bronstein
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

Review 6.  Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results.

Authors:  E D Clarkson
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

Review 7.  Cell-based therapy for Parkinson's disease: A journey through decades toward the light side of the Force.

Authors:  Malin Parmar; Olof Torper; Janelle Drouin-Ouellet
Journal:  Eur J Neurosci       Date:  2018-09-09       Impact factor: 3.386

8.  Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study.

Authors:  Rosaria Giordano; Margherita Canesi; Maurizio Isalberti; Ioannis Ugo Isaias; Tiziana Montemurro; Mariele Viganò; Elisa Montelatici; Valentina Boldrin; Riccardo Benti; Agostino Cortelezzi; Nicola Fracchiolla; Lorenza Lazzari; Gianni Pezzoli
Journal:  J Transl Med       Date:  2014-01-17       Impact factor: 5.531

Review 9.  Cell based therapies in Parkinson's Disease.

Authors:  Madhuri Behari; Kapil Kumar Singhal
Journal:  Ann Neurosci       Date:  2011-04

Review 10.  Improved Delivery Methods for Gene Therapy and Cell Transplantation in Parkinson's Disease.

Authors:  Paul S Larson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.